Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAPACE: NAC for Radiation Protection in Catheter Ablation
NCT04154982Phase 2Completed
- Sponsor
- Centro Cardiologico Monzino
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of acetylcysteine in radiation-induced cellular damage, sponsored by Centro Cardiologico Monzino. Primary endpoint: Change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α, 8-OHdG) and genomic DNA oxidative damage at 48 hours. Started Sep 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
radiation-induced cellular damage
Beyond the preview
Go deeper on NCT04154982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154982.